M&A

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

Sales & Marketing

pharmaphorum podcast Episode 268 - Andrea Carta Mantiglia, BonelliErede

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, discusses M&A in Europe.

News

Vertex buys Crinetics for $10bn in endocrinology drive

Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.

News

Novartis snaps up UK ADC developer Myricx Bio

Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

News